A study to compare continuation rates between Yasmin® and existing combined oral contraceptives in UK clinical practice

A study to compare continuation rates between Yasmin® and existing

combined oral contraceptives in UK clinical practice

D. Mansour (1), S. Lister (2)

Newcastle General Hospital, Newcastle, UK (1); CompuFile Ltd., Woking,

Surrey, UK (2)

Introduction: Large comparative trials have shown Yasmin (30 µg

ethinylestradiol/3 mg drospirenone) to have a contraceptive reliability and

cycle control comparable with existing combined oral contraceptives (COCs).

Drospirenone is a new progestogen unlike those found in existing COCs, having a

pharmacological profile more closely related to natural progesterone.

Noncomparative studies of Yasmin have demonstrated an improvement in

androgen-related skin conditions, together with an improvement in some symptoms

of premenstrual problems related to water retention.

Aims and Methods: To investigate if, in clinical practice, the

pharmacological profile and non-contraceptive properties of Yasmin result in a

higher continuation rate than those observed with existing COCs. Data were

gathered from 163 nationally distributed GP practices across Great Britain.

Women who met the inclusion criteria were followed for 12 months. An agematched

comparator cohort of women using other COCs was drawn from the same practices

concomitantly. Discontinuation of Yasmin or a comparator COC was defined as

failure to return for another prescription for the same product within 1 cycle

(4 weeks) of the end of the first prescription. Pregnancy, or the use of

alternative contraception (excluding condoms, spermicides and emergency

contraception), were also defined as discontinuation.

Results: Data from 632 women (mean age 27 years) were analysed. A

significantly higher proportion of women in the Yasmin cohort continued to take

their pill, compared with the comparator arm (8.5%, p=0.022). Additionally,

women taking Yasmin were found to continue their pill for significantly longer

than those in the comparator cohort (+35 days over a 12-month period) (p <0.001).

Source of data: DIN-LINK data, CompuFile Ltd., November 2003

Conclusions: This study showed that continuation rates with Yasmin are

significantly higher compared with comparator COCs. As the contraceptive

efficacy and cycle control of Yasmin is comparable with existing COCs, it may be

that the higher continuation rate is attributable to its pharmacological profile

and associated non-contraceptive properties.

Scroll to Top